ArticleEuropean journal of drug metabolism and pharmacokinetics2020

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.

Robert Shumaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.